Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519446 | 0.94 | LMNA (0.39) | GAALMNATDP1L3MBTL1NPC1 | |
| SCHEMBL6513801 | 0.88 | ALDH1A1 (0.42) | LMNANPC1CYP19A1HPGDRAB9A | |
| SCHEMBL6520993 | 0.87 | ALDH1A1 (0.40) | LMNAL3MBTL1MEN1KMT2ACYP19A1 | |
| SCHEMBL6515222 | 0.87 | LMNA (0.43) | GAALMNAL3MBTL1MAPTMEN1 | |
| SCHEMBL6519526 | 0.85 | ALDH1A1 (0.42) | LMNANPC1MAPTKMT2AHPGD | |
| SCHEMBL6521080 | 0.85 | ALDH1A1 (0.42) | LMNANPC1MAPTKMT2AHPGD | |
| SCHEMBL6518880 | 0.84 | GAA (0.51) | GAALMNATDP1L3MBTL1NPC1 | |
| SCHEMBL6513746 | 0.83 | GAA (0.50) | GAALMNATDP1L3MBTL1NPC1 | |
| SCHEMBL6522170 | 0.82 | ALDH1A1 (0.43) | LMNAL3MBTL1MEN1KMT2ACYP19A1 | |
| SCHEMBL6520983 | 0.81 | KMT2A (0.42) | GAALMNATDP1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958366-B2 | Antifouling coating composition and novel resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20030118544-A1 | Antifouling coating composition and novel resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118544-A1 | Antifouling coating composition and novel resin | COL1A1, GLRA1, COL2A1 | GAA 3231/4885LMNA 2459/4885TDP1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.